Harris Dorathy-Ann, Park Ji-Min, Lee Kyung-Soon, Xu Cong, Stella Nephi, Hague Chris
Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington.
Departments of Pharmacology (D.-A.H., J.-M.P., K.-S.L., C.X., N.S., C.H.) and Psychiatry and Behavioral Sciences (C.X., N.S.), University of Washington School of Medicine, Seattle, Washington
J Pharmacol Exp Ther. 2017 May;361(2):219-228. doi: 10.1124/jpet.116.237255. Epub 2017 Feb 14.
Small molecules that target the adrenergic family of G protein-coupled receptors (GPCRs) show promising therapeutic efficacy for the treatment of various cancers. In this study, we report that human colon cancer cell line SW480 expresses low-density functional -adrenergic receptors (ARs) as revealed by label-free dynamic mass redistribution (DMR) signaling technology and confirmed by quantitative reverse-transcriptase polymerase chain reaction analysis. Remarkably, although endogenous -ARs are not detectable via either [H]-prazosin-binding analysis or phosphoinositol hydrolysis assays, their activation leads to robust DMR and enhanced cell viability. We provide pharmacological evidence that stimulation of -ARs enhances SW480 cell viability without affecting proliferation, whereas stimulating -ARs diminishes both viability and proliferation of SW480 cells. Our study illustrates the power of label-free DMR technology for identifying and characterizing low-density GPCRs in cells and suggests that drugs targeting both - and -ARs may represent valuable small-molecule therapeutics for the treatment of colon cancer.
靶向G蛋白偶联受体(GPCR)肾上腺素能家族的小分子在治疗各种癌症方面显示出有前景的治疗效果。在本研究中,我们报告称,通过无标记动态质量再分布(DMR)信号技术揭示并经定量逆转录酶聚合酶链反应分析证实,人结肠癌细胞系SW480表达低密度功能性β-肾上腺素能受体(ARs)。值得注意的是,尽管通过[H]-哌唑嗪结合分析或磷酸肌醇水解试验均无法检测到内源性β-ARs,但其激活会导致强烈的DMR并增强细胞活力。我们提供了药理学证据,表明刺激β-ARs可增强SW480细胞活力而不影响增殖,而刺激α-ARs则会降低SW480细胞的活力和增殖。我们的研究说明了无标记DMR技术在识别和表征细胞中低密度GPCR方面的作用,并表明靶向α-和β-ARs的药物可能是治疗结肠癌的有价值的小分子疗法。